@article{3118845,
    title = "Morphometric analysis of fibrovascular pigment epithelial detachments treated with ranibizumab and aflibercept",
    author = "Karampelas, M. and Syriga, M. and Petrou, P. and Georgalas, I. and Papaconstantinou, D. and Brouzas, D.",
    journal = "European Journal of Ophthalmology",
    year = "2022",
    volume = "32",
    number = "1",
    pages = "347-355",
    publisher = "SAGE Publications Ltd",
    issn = "1120-6721, 1724-6016",
    doi = "10.1177/11206721211005706",
    keywords = "aflibercept;  ranibizumab;  aflibercept;  angiogenesis inhibitor;  fusion protein;  ranibizumab;  vasculotropin receptor, age related macular degeneration;  aged;  Article;  B scan;  Bruch membrane;  cohort analysis;  controlled study;  female;  fluorescence angiography;  human;  image analysis;  image segmentation;  indocyanine green angiography;  major clinical study;  male;  morphometry;  ophthalmoscopy;  optical coherence tomography;  retina detachment;  retinal pigment epithelium;  retrospective study;  spectral domain optical coherence tomography;  very elderly;  visual acuity;  intravitreal drug administration;  retinal pigment epithelium, Angiogenesis Inhibitors;  Humans;  Intravitreal Injections;  Ranibizumab;  Receptors, Vascular Endothelial Growth Factor;  Recombinant Fusion Proteins;  Retinal Pigment Epithelium;  Retrospective Studies;  Tomography, Optical Coherence",
    abstract = "Purpose: To assess fibrovascular pigment epithelial detachments (PED) and their response to two different anti-VEGF agents using optical coherence tomography (OCT) morphometric analysis. Methods: Seventy-three consecutive, treatment-naïve eyes with fibrovascular PED (>125 μm) treated with ranibizumab or aflibercept were retrospectively included. A custom-made software was used to manually segment and calculate PED maximum height, base area, volume and internal reflectivity at baseline, after three injections and 1 year. Results: Visual acuity (VA) change was 2 ETDRS letters ± 7.6 after three injections and 3.2 ETDRS letters ± 10.3 at 1 year. There was no significant difference between VA changes amongst the two drugs. At 1 year, anti-VEGF treatment resulted in a mean reduction of 125 μm in maximum PED height, of 2.26 mm2 in base area and of 0.54 mm3 in volume with a corresponding increase in reflectivity. These changes were more prominent in the aflilbercept group. The observed PED and VA changes at year 1 were strongly correlated with their values at baseline and after three injections. Conclusions: Anti-VEGF treatment resulted in a reduction of all PED dimensions and a corresponding increase in optical reflectivity. Higher, larger and more hypo-reflective PEDs demonstrated a better anatomical response, especially with aflibercept, but this was not correlated with VA. © The Author(s) 2021."
}